The Lancet. Global health
-
The Lancet. Global health · Apr 2019
Randomized Controlled TrialEffect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: a cluster-randomised controlled trial.
Novartis Access is a Novartis programme that offers a portfolio of non-communicable disease medicines at a wholesale price of US$1 per treatment per month in low-income and middle-income countries. We evaluated the effect of Novartis Access in Kenya, the first country to receive the programme. ⋯ Sandoz International (a subsidiary of Novartis International).